Two decades of Alzheimer’s research was based on deliberate fraud by 2 scientists that has cost billions of dollars
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, …